Brief: Vectivbio And Asahi Kasei Pharma Announce The Start Of A Phase 1 Study Of Apraglutide In Japan
March 13 (Reuters) - Asahi Kasei Corp 3407.T :
* VECTIVBIO AND ASAHI KASEI PHARMA ANNOUNCE THE START OF A
PHASE
1 STUDY OF APRAGLUTIDE IN JAPAN
Source text for Eikon: ID:nGNXX5gw0
Further company coverage: 3407.T
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ASAHI KASEI
See all newsBrief: Asahi Kasei Corporation - Subsidiary To Launch Tender Offer For Shares Of Mori-Gumi
Table: ASAHI KASEI -6-MTH group results
Brief: Asahi Kasei Corporation - Announces Cancellation Of Treasury Shares
US FDA approves Asahi Kasei's drug for persistent herpes infections
Table: Asahi Kasei -Q1 group results